The Vascular Effects of Carvedilol Controlled Release (CR) in Abdominally Obese Hypertensive Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
Abdominal ObesityHypertension
Interventions
DRUG

Carvedilol CR + Lisinopril

Participants were given Carvedilol CR + Lisinopril for three months. Oral medication. Carvedilol CR and Lisinopril combination therapy was initiated at 20 mg and 10 mg, respectively. Patients returned one week later and doses of carvedilol CR and lisinopril were increased to 40 mg and 20 mg, respectively, depending on blood pressure.

DRUG

Lisinopril + HCTZ

Participants were given Lisinopril + HCTZ for three months. Oral medication. Lisinopril + HCTZ combination therapy was initiated at 12.5 mg and 10 mg, respectively. Patients returned 1 week later and doses of hydrochlorothiazide and lisinopril were increased to 25 mg and 20 mg, respectively, depending on blood pressure levels.

Trial Locations (1)

55102

St. Paul Heart Clinic, Saint Paul

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

St. Paul Heart Clinic

OTHER

NCT00459056 - The Vascular Effects of Carvedilol Controlled Release (CR) in Abdominally Obese Hypertensive Patients | Biotech Hunter | Biotech Hunter